TY  - JOUR
T1  - Metaplastic carcinoma of the breast: A report of two cases along with review of literature
A1  - Shivani Sood
A1  - Vidisha Mahajan
A1  - Vijay Kaushal
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2014
VL  - 3
IS  - 4
DO  - 10.4103/2278-0513.134500
SP  - 335
EP  - 337
N2  - Metaplastic carcinomas of breast are uncommon, representing 0.3% of invasive carcinomas of breast. We are reporting two cases of metaplastic carcinoma breast, one revealing rhabdomyoblastic and spindle cell differentiation and other revealing osteoclast like giant cells. Both were estrogen receptor, progesterone receptor and Her2u negative on immunohistochemistry. Early diagnosis of metaplastic carcinomas is essential as these tumors are usually triple negative and hence, do not respond to transtuzumab. Metaplastic carcinomas typically express HER1/epidermal growth factor receptor (EGFR), thus majority of metaplastic carcinomas are treated with EGFR inhibitors such as geftinib and cetuximab. Also, metaplastic carcinomas are associated with a worse prognosis with a disease free survival rate being 78.1% in metaplastic breast carcinomas compared with 91% in infiltrating duct carcinomas.
UR  - https://ccij-online.org/article/metaplastic-carcinoma-of-the-breast:-a-report-of-two-cases-along-with-review-of-literature-237
ER  -